Stallimycin

Summary

Stallimycin (distamycin A) is a naturally occurring oligopeptide antibiotic produced by Streptomyces distallicus. It binds non-covalently to the minor groove of B-form DNA at AT-rich regions, inhibiting RNA and DNA synthesis. It has demonstrated antiviral, antibacterial, and antitumor activities in vitro and in vivo, but has not progressed to clinical approval due to toxicity concerns. It served as the parent scaffold for numerous synthetic analogues (lexitropsins, tallimustine) developed in cancer and antiviral research.

Mechanism of Action

Binds to the minor groove of double-stranded DNA at AT-rich sequences, inhibiting DNA-directed RNA synthesis and DNA replication by physically blocking transcription and replication machinery.

Routes of Administration

Goals & Uses

• Antitumor activityOncologyLow
• Antiviral activityInfectious DiseaseLow
• Research tool for DNA-binding studiesBiochemical ResearchHigh
• Antibacterial activityInfectious DiseaseLow

Contraindications

• Known hypersensitivity to distamycin or related oligopeptidesAllergyHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data

Adverse Effects

• Local irritationDermatologicUnknown
• Gastrointestinal toxicityGastrointestinalUnknown
• MyelosuppressionHematologicUnknown
• NephrotoxicityRenalUnknown

Drug Interactions

• Alkylating agentsModerate
• Other DNA-intercalating or groove-binding agentsHigh

Population Constraints

• Pediatric populationsAgeRelative
• Patients with pre-existing bone marrow suppressionHematologicRelative
• Pregnant womenReproductiveAbsolute

Regulatory Status

• European UnionUnapprovedNot approved by EMA; research/investigational use only.
• United StatesUnapprovedResearch use only; not FDA-approved for any indication.
• United KingdomUnapprovedNot approved by MHRA; used only in research contexts.

Not approved by any major regulatory authority (FDA, EMA, MHRA) for clinical use. Used exclusively as a research tool compound and as a pharmacophore template for drug design.

Evidence & Sources

No sources recorded yet.